ImClone expected to get Erbitux approved by FDA this time

02/11/2004 | NYTimes.com

The drug that was rejected by the FDA, sparking a Wall Street scandal, is back before the agency for approval, with ImClone Systems making a new effort to get the agency's OK for its cancer drug. Analysts believe better clinical trial data are available this time, and the FDA is expected to give its approval before the deadline for a decision expires this week.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ